Abstract: A traditional Chinese medicinal composition is prepared from Herba schizonepetae, Radix saposhnikoviae, Notopterygium root, Radix angelicae pubescentis, Radix bupleuri, common hogfennel root, Rhizoma chuanxiong, Fructus aurantii, Poria cocos, Radix platycodonis, and liquorice root. The traditional Chinese medicinal composition can reduce the cough frequency of a guinea pig model with cough variant asthma, a percentage of eosinophils in a bronchoalveolar lavage fluid, and a level of serum eosinophil cationic proteins, and has a prevention and treatment effect on the cough variant asthma.

Abstract: Association comprising: Bacopa monnieri dry extract, Astaxanthin powder, Vitamin E, phosphatidylserine and Withania somnifera and optionally an association of an aqueous extract of Salvia officinalis and an oily extract of Salvia lavandulifolia, for use as a coadjuvant in the prevention of Alzheimer's disease, as it is capable of reducing some of the main modifiable risk factors of cognitive decline associated with Alzheimer's disease and consequently improving memory and cognitive functions.

Abstract: Provided is a composition for anti-inflammatory, antioxidant, anti-wrinkle or hair health promotion containing an extract mixture of Ziziphus jujuba Miller, Citrus unshiu Peel, and Acorus calamus as an active ingredient. The extract mixture of Ziziphus jujuba Miller, Citrus unshiu Peel, and Acorus calamus decreases the expression of MMP-1 and MMP-13 in fibroblasts and decreases the expression and production of IL-1P and IL-6 by LPS in macrophages to have anti-inflammatory and anti-wrinkle effects. In addition, the extract mixture of Ziziphus jujuba Miller, Citrus unshiu Peel, and Acorus calamus has DPPH radical scavenging activity to have an antioxidant effect. The hair using the extract mixture of Ziziphus jujuba Miller, Citrus unshiu Peel, and Acorus calamus is increased in tensile strength and has an effect of improving a cuticle layer of the hair, thereby having a hair health promotion effect.

Abstract: The present invention discloses an improved process for preparing enriched extracts containing Mitragynine from the plant Mitragyna speciosa. The present invention discloses simple processes for preparing such enriched extracts of Mitragynine from Mitragyna speciosa using simple and commonly available solvents and inexpensive techniques. More particularly, the present invention relates to preparation of Mitragynine enriched extract using alkaline water solution.

Abstract: The present invention discloses a process for purification of Mitragynine or preparation of purified Mitragynine salt from crude Mitragynine extract for the pharmaceutical preparations. More particularly, the present invention discloses purification of Mitragynine or preparation of purified Mitragynine salt using polar aprotic solvents.

Abstract: The present invention relates to a composition for the prevention or treatment of a muscle disease, comprising an extract of Ponciri Fructus. The extract of the present invention has the effect of increasing the expression of genes related to myotube cell differentiation and/or athletic performance, increasing muscle weight, and/or improving athletic performance.

Abstract: The present invention relates to a composition for the treatment of colon disorder comprising oil palm polyphenolics (OPP) and fibres extracted from the vegetation liquor generated during the milling and extraction of oil from the oil palm fruit administered to a patient in an effective concentration of 50 mg gallic acid equivalents (GAE). The present invention further relates to a method of treatment and prevention of colon disorders and maintenance of gut health.

Abstract: A fermentation complex with increasing generation of brain dopamine and improving sleeping effect, the fermentation complex containing a vegetable ingredient and use a special polysaccharide fermentation preparation method to get a fermentation complex, within the vegetable ingredient include Gastrodia elata, Black rice, and Wheat seedlings. The fermentation complex has effect of delaying brain aging, protecting brain nerves, calming nerves, and helping to fall asleep.

Abstract: Provided is composition for preventing and treating depression, including complex extracts of Zizyphi spinosi Semen, Jujubae Fructus, Hordei Fructus Germinatus, Glycyrrhizae Radix et Rhizoma, Angelicae Gigantis Radix, and Beta vulgaris as active ingredients. The complex extracts including Zizyphi spinosi Semen, Jujubae Fructus, Hordei Fructus Germinatus, Glycyrrhizae Radix et Rhizoma, Angelicae Gigantis Radix, and Beta vulgaris have an antidepressant effect and an effect on the expression of proteins related to antidepressant action. The complex extracts of the present disclosure may be effectively used as a composition for preventing and treating depression.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: This disclosure provides pharmaceutical preparations, products, and methods relating to ARINA-1 for use in treating patients with chronic inflammatory lung diseases, such as lung transplant, cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD, and other inflammatory lung diseases.

Abstract: Pharmaceutical compositions are provided, comprising at least one selective CB2 receptor agonist and at least one steroid. The provided compositions are effective in treating inflammation and/or pathogen related inflammation and associated complications thereof. Also provided are methods for treating a subject infected with a pathogen as well as inflammation, using said compositions.

Abstract: Treatment of chronic eye conditions further aims to prevent or delay the onset of irreversible vision impairment. Provided herein are methods and compositions for treating ocular diseases, disorders, and conditions. Described are compositions and methods for preventing, treating, or ameliorating an inflammation-mediated disease or condition in an individual comprising administering to the subject a Fas inhibitor, its derivative, or a pharmaceutically acceptable salt thereof.

Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.

Abstract: Described herein are bacteriocin peptides, peptidomimetics, compositions, pharmaceutical compositions, and cosmetic compositions comprising same. Aspects and embodiments described herein may be used in medical treatment, disinfection of surfaces and cosmetics.

Abstract: Described herein is a novel, mitochondrial encoded, open reading frame that leads to the production of a new mitochondrial peptide called SHMOOSE. SHMOOSE is a 58-amino-acid peptide and, within its open reading frame, contains a genome-wide significant small nucleotide polymorphism (SNP) that markedly increased risk for Alzheimer's disease, brain structure, brain gene expression, and cognition. SHMOOSE increased neuronal-type cell survival and protected against amyloid beta toxicity. Metabolomic studies revealed a role for the peptide in energy optimization, whose dysfunction and dysregulation leads to cell death in physiologically notable regions of the brain in neurodegenerative diseases such as Alzheimer's and Parkinson's. Methods and compositions, including peptide analogues and derivatives, are described for treatment and diagnostics.

Abstract: Methods for preventing neural tube defects in embryos of diabetic females via administration of Survivin-containing exosomes derived from Flk-1+ mesoderm progenitor cells are reported.

Abstract: The invention provides methods and kits for inducing satiety and treatment of metabolic disorders, diabetes, obesity, and obesity-related conditions. The methods and kits herein described include administration of a metabolic hormone and a GLP-1 receptor agonist for inducing satiety or treatment of metabolic syndrome, diabetes, obesity, and obesity-related disorders.

Abstract: This application is directed to methods of treating Graft versus Host Disease (GvHD), specifically acute GvHD and acute gastrointestinal GvHD, using apraglutide.

Abstract: Provided are a use, a pharmaceutical composition, and a method for efpeglenatide for reducing a risk of developing a cardiovascular disease or renal dysfunction. The efpeglenatide may be used for cardiovascular or renal protection of patients having type 2 diabetes who have or are at risk of a cardiovascular disease or renal disease.

Abstract: Compositions of peptide fragments of preproinsulin for the treatment of type 1 diabetes and methods for selecting one or more peptide fragments of preproinsulin suitable for subject-specific immunomodulatory therapy for type 1 diabetes. The one or more peptides may be selected based on an autoimmune phenotype for the subject, which may be characterized by a stimulation assay and/or the based on a genotype for one or more genes related to type 1 diabetes.

Abstract: Disclosed herein are methods for enhancing an immune response in an individual in need thereof. The methods, in certain aspects, may comprise administering bacterial aldehyde dehydrogenase, a bacteria that produces aldehyde dehydrogenase, or combinations thereof to an individual. Further disclosed are compositions, such as nutritional compositions, which may comprise bacterial aldehyde dehydrogenase, a bacteria that produces aldehyde dehydrogenase, or combinations thereof.

Abstract: The invention relates to composition and methods for expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) in a living organism. In preferred embodiments, the invention relates to treating disease condition that involves use of therapeutically effective amount of a composition described herein.

Abstract: The present invention relates to compositions and methods of wound debridement and stimulation of granulation tissue formation, thereby preparing the wound bed to facilitate and promote the process of wound healing. In particular, the present invention relates to methods of debridement of chronic wounds by topically applying to a wound site or bed a composition containing a proteolytic enzyme mixture obtained from bromelain and a water-soluble gelling agent, the composition being applied to the wound site or bed up to ten times over a period of up to four weeks, resulting in a clean wound bed covered with granulation tissue prepared towards wound healing.

Abstract: The present invention relates to the field of medicine, specifically to the prevention and treatment of pre-eclampsia.

Abstract: The present invention relates to a specific administration scheme of an immunogenic peptide comprising T cell epitope of an antigen and an oxidoreductase motif.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of KRAS neoepitope-encoding sequences and/or lacking immunodominant epitopes. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

Abstract: This disclosure features human Lymphocyte-activation gene 3 (LAG3) and human Galectin-3 (GAL3) inhibitory agents, immunogenic peptides X-Box Binding Protein 1 (XBP1), CD2 Subset 1 (CS1), and CD138 peptides, and methods of using the inhibitory agents and peptides to treat blood cancers and pre-cancerous conditions.

Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.

Abstract: An mRNA composition for malaria prevention and treatment comprising a coding mRNA capable of expressing proteins and peptides of malaria pathogens, coming from linear epitopes and protein structure of antigens.

Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one particular insecticide disclosed herein in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one particular insecticide disclosed herein in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one particular fungicide disclosed herein in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

Abstract: Group A Streptococcus (GAS) is associated with an estimated half-million deaths per year and 21 severe autoimmune sequalae. Despite the ubiquity of GAS infection, no vaccine currently exists. Provided herein is a Streptococcus S protein or an equivalent thereof used as a vaccine, along with the related compositions and methods.

Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.

Abstract: Provided herein are veterinary viral vectors and vaccines based on genetically engineered Pichinde viruses that include three or more genomic segments. The first genomic segment includes a coding region encoding a Z protein and a coding region encoding a L RdRp protein. The second genomic segment includes a coding region encoding a nucleoprotein (NP) and the third genomic segment includes a coding region encoding a glycoprotein. At least one of the second and third genomic segments further includes a donor gene sequence encoding an adenovirus capsid protein in full length or any functional fragment thereof. Further provided are methods for using a reverse genetics system, and methods for producing an immune response against adenovirus or Hemorrhagic Enteritis Virus (HEV) infection of a subject such as a turkey.

Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

Abstract: Disclosed herein are hybrid multivalent vaccine or immunogenic compositions comprising (i) one or more influenza virus proteins selected from one or more influenza virus hemagglutinin (HA) proteins, one or more influenza virus neuraminidase (NA) proteins, or a combination thereof; and (ii) one or more ribonucleic acid molecules encoding one or more influenza virus proteins selected from one or more influenza virus HA proteins, one or more influenza virus NA proteins, or a combination thereof. Also disclosed are methods of using the vaccine or immunogenic compositions.

Abstract: Designed coronavirus polypeptide sequences are described, and their use as vaccines against viruses of the coronavirus family. The designed sequences include designed coronavirus spike (S) proteins and fragments thereof, including designed S protein receptor binding domain (RBD) sequence SEQ ID NO:17, designed truncated S protein sequence SEQ ID NO:15, and designed full length S protein sequence SEQ ID NO:13. Designed coronavirus envelope (E), membrane (M), and nucleocapsid (N) protein sequences are also described, and their use as vaccines. Nucleic acid molecules encoding the polypeptides, vectors, fusion proteins, pharmaceutical compositions, cells, and their use as vaccines against viruses of the coronavirus family are also described.

Abstract: The disclosure provides a C-terminally truncated Spike protein of PEDV. Nucleic acid sequences including same and a virus comprising same, as well as methods of use are also provided.

Abstract: Disclosed are immunogens for stimulating an immune response to coronaviruses. The immunogens can be non-receptor binding domain (RBD) epitopes. The immunogens can be grafted into a scaffold polypeptide to produce an epitope scaffold. Antibodies induced by the immunogens are disclosed.

Abstract: The disclosure provides mRNA vaccines which encode for coronavirus spike proteins exhibiting increased flexibility in the crown of the helix turn region. This increased flexibility is achieved by at least two glycine mutations within the crown of the helix turn region, located between the HR1 and CH regions.

Abstract: The present invention relates to immunisation using carrier-formulated mRNA in conjunction with an adjuvant comprising a STING agonist, and to related aspects.

Abstract: Provided herein are methods for inducing tolerance to an organ or tissue transplant in a patient. Specifically, provided herein are methods for inducing temporary mixed chimerism in a transplant-eligible patient, wherein the method comprises administering an anti-CD2 antibody or antigen binding fragment thereof to the patient, transplanting bone marrow from a donor to the patient; and administering at least one other agent prior to and/or after transplant to the patient.

Abstract: The present invention provides compositions and methods comprising CAR T cells that secrete neuraminidase (e.g., C. perfringens neuraminidase (CpNA)). Compositions and methods of treatment are also provided.

Abstract: Provided is a method of activating a recombinant immune cell expressing a synthetic receptor comprising an intracellular domain derived from killer cell immunoglobulin-like receptor 4 (KIR2DL4). Synthetic receptors described herein allow for the activation of recombinant immune cells against an antigen of interest without the deleterious effects of immune cell hyperactivation by existing CARs. The recombinant immune cells can thus be used to in the treatment of cancers or infectious diseases in subjects in need thereof, while limiting the hyperactivation of an immune response associated with traditional recombinant cell-based therapies.

Abstract: The presently disclosed subject matter provides novel T cell receptors (TCRs) that target a mutated RAS protooncogene. The presently disclosed subject matter further provides cells comprising such TCRs. and methods of using such cells for treating cancers associated with RAS.

Abstract: The present disclosure relates to promoter constructs comprising: one or more heat shock elements: a core promoter; and a gene of interest: vectors comprising the promoter constructs, and immune cells modified to include the promoter constructs. The promoter constructs provide the ability to remotely control immune cell therapies by thermal targeting. The present disclosure also provides methods of use for the promoter constructs.

Abstract: Provided is a treatment method for administration of immune effector cells to an individual suffering from or suspected of suffering from a CLD18 positive biliary tract tumor, comprising administrating immune effector cells that specifically recognize CLD18.2 to an individual. Pretreatment is performed and then the immune effector cells of the present application are administrated, so that the tumor treatment efficacy of the immune effector cells can be remarkably improved.